<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:mp ids='MP_0002038'>Carcinoma</z:mp> cells enhance their invasive capacity through <z:e sem="disease" ids="C0002793" disease_type="Neoplastic Process" abbrv="">dedifferentiation</z:e> and dissolution of intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesions</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A key activator of this process is the ZEB1 transcription factor, which is induced in invading <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells by canonical Wnt signaling (Î²-catenin/TCF4) </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> invasiveness also entails proteolytic remodeling of the peritumoral stroma </plain></SENT>
<SENT sid="3" pm="."><plain>This study aimed to investigate the potential regulation by ZEB1 of the plasminogen proteolytic system constituted by the urokinase plasminogen activator (uPA), and its inhibitor, plasminogen activator inhibitor-1 (PAI-1) </plain></SENT>
<SENT sid="4" pm="."><plain>EXPERIMENTAL DESIGN: Through multiple experimental approaches, colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cell lines and samples from human primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and ZEB1 (-/-) mice were used to examine ZEB1-mediated regulation of uPA and PAI-1 at the protein, <z:chebi fb="2" ids="33699">mRNA</z:chebi>, and transcriptional level </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: ZEB1 regulates uPA and PAI-1 in opposite directions: induces uPA and inhibits PAI-1 </plain></SENT>
<SENT sid="6" pm="."><plain>In vivo expression of uPA depends on ZEB1 as it is severely reduced in the developing intestine of ZEB1 null (-/-) mice </plain></SENT>
<SENT sid="7" pm="."><plain>Optimal induction of uPA by Wnt signaling requires ZEB1 expression </plain></SENT>
<SENT sid="8" pm="."><plain>ZEB1 binds to the uPA promoter and activates its transcription through a mechanism implicating the <z:chebi fb="0" ids="15358">histone</z:chebi> acetyltransferase p300 </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, inhibition of PAI-1 by ZEB1 does not involve transcriptional repression but rather downregulation of <z:chebi fb="2" ids="33699">mRNA</z:chebi> stability </plain></SENT>
<SENT sid="10" pm="."><plain>ZEB1-mediated <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumor cell migration</z:e> and invasion depend on its induction of uPA </plain></SENT>
<SENT sid="11" pm="."><plain>ZEB1 coexpresses with uPA in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells at the invasive front of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: ZEB1 promotes <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> invasiveness not only via induction in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells of a motile dedifferentiated phenotype but also by differential regulation of genes involved in stroma remodeling </plain></SENT>
</text></document>